Recombinant methionyl human granulocyte colony-stimulating factor for the prevention and treatment of non-neutropenic infectious diseases.
Recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF, hereafter G-CSF) has been demonstrated in clinical trials to be effective in correcting iatrogenic neutropenia by stimulating the production of neutrophils. Not surprisingly, G-CSF has also been found to induce neutrophilia in non-neutropenic hosts. Experimental data suggest that G-CSF leads to the enhancement of neutrophil function. Endogenous G-CSF levels are elevated over a broad spectrum of serious infectious diseases, suggesting the clinical importance of G-CSF in these settings. These findings have stimulated research on the use of G-CSF alone or as an adjunct to conventional antimicrobial therapy in a number of non-neutropenic animal models of infections. In total these studies suggest that G-CSF may be useful in the prevention or therapy of infections in both non-neutropenic and neutropenic clinical settings.
Daifuku
R
R
Amgen, Thousand Oaks, CA 91320-1789.
Andresen
J
J
Morstyn
G
G
D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy* / Q000517:prevention & control; D002056:Burns / Q000382:microbiology; D004195:Disease Models, Animal; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D051379:Mice; D009503:Neutropenia / Q000188:drug therapy / Q000517:prevention & control; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D011014:Pneumonia / Q000188:drug therapy / Q000517:prevention & control; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors; D014946:Wound Infection / Q000188:drug therapy / Q000517:prevention & control
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor